A network meta-analysis of direct factor Xa inhibitors for the treatment of cancer-associated venous thromboembolism.

Gustavo Muçouçah Sampaio BrandãoRafael D MalgorTarsila VieceliRaissa Carolina Fonseca CândidoJosé Francisco Secorun InácioClarissa Garcia RodriguesEmily A MalgorMarcone Lima Sobreira

Published in: Vascular (2021)

DOAs presented a reduced risk of recurrent VTE with similar risk of major bleeding compared to Dalteparin. However, a higher risk of CRNMB is expected when this cohort of patients are treated with DOAs instead of Dalteparin.

Keyphrases

venous thromboembolism
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
direct oral anticoagulants
prognostic factors
peritoneal dialysis
combination therapy
smoking cessation